



# BD SARS-CoV-2 Reagents for BD MAX™ System

**REF 445003-01**

For Emergency Use Authorization (EUA) only

For *In Vitro* Diagnostic Use

For use with the BD MAX™ System

P0252(05)

2020-09

English



**R<sub>x</sub> Only**

## INTENDED USE

The BD SARS-CoV-2 Reagents for BD MAX™ System is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in nasopharyngeal, nasal, mid-turbinate, and oropharyngeal swab specimens, nasopharyngeal wash/aspirate or nasal aspirates obtained from individuals suspected of COVID-19 by their healthcare provider. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet requirements to perform moderate or high complexity tests.

Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in upper respiratory samples during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. Positive results should be treated as presumptive and should be tested with a different authorized or cleared molecular test. The agent detected may not be the definite cause of disease. Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.

The BD SARS-CoV-2 Reagents for BD MAX System is intended for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR, *in vitro* diagnostic procedures, and use of the BD MAX System. The BD SARS-CoV-2 Reagents for BD MAX System is only for use under the Food and Drug Administration's Emergency Use Authorization.

## EXPLANATION OF THE TEST

Total nucleic acid (TNA) is isolated and purified using BD SARS-CoV-2 Reagents for BD MAX System from nasal, nasopharyngeal, or oropharyngeal swabs collected in BD Universal Viral Transport System (UVT) or Copan Universal Transport Media System (UTM) and nasal swabs collected in 0.85% saline. Patient sample is transferred to the Sample Buffer Tube provided with the BD SARS-CoV-2 Reagents for BD MAX System and placed in the BD MAX System.

The BD MAX ExK™ TNA-3 unitized reagent strip contains a combination of lytic and extraction reagents designed to perform cell lysis and TNA extraction. Eluted TNA is transferred to SARS-CoV-2 primers and probes and to the BD MAX TNA MMK master mix. The final rehydrated master mix is transferred to a PCR cartridge for rRT-PCR.

The BD SARS-CoV-2 Reagents for BD MAX System utilizes multiplexed primers and probes targeting RNA from the nucleocapsid phosphoprotein gene (N1 and N2 regions) of the SARS-CoV-2 coronavirus, and the human RNase P gene. The primer and probe sets are based on the United States Centers for Disease Control and Prevention (US CDC) assay for specific detection of SARS-CoV-2 by amplifying two unique regions of the N gene (i.e., N1 and N2).

An internal control targeting the human RNase P gene will be co-amplified along with N1 and N2 gene targets (if present) and will serve as an endogenous nucleic acid extraction control present in all properly collected patient samples. This control serves as both an extraction control and an internal amplification control.

## PRINCIPLES OF THE PROCEDURE

A combination of lytic and extraction reagents is used to perform cell lysis and DNA/RNA extraction. Nucleic acids released from the target organisms are captured on magnetic affinity beads. The beads, together with the bound nucleic acids, are washed and the nucleic acids are eluted by a combination of heat and pH variation. Neutralization buffer is used to rehydrate BD SARS-CoV-2 Reagents for BD MAX System Primers and Probes. Eluted TNA is added to the rehydrated primers and probes, mixed, and transferred to BD MAX TNA MMK master mix for rehydration. After reconstitution, the BD MAX System dispenses a fixed volume of RT-PCR-ready solution containing extracted nucleic acids into the PCR Cartridge. Microvalves on the cartridge are sealed by the system prior to initiating PCR in order to contain the amplification mixture and thus prevent evaporation and contamination.

The amplified cDNA targets are detected using hydrolysis (TaqMan®) probes, labeled at one end with a fluorescent reporter dye (fluorophore), and at the other end, with a quencher moiety. Probes labeled with different fluorophores are used to detect the target analytes in different optical channels of the BD MAX System. When the probes are in their native state, the fluorescence of the fluorophore is quenched due to its proximity to the quencher. However, in the presence of target cDNA, the probes hybridize to their complementary sequences and are hydrolyzed by the 5'–3' exonuclease activity of the DNA polymerase as it synthesizes the nascent strand along the cDNA template. As a result, the fluorophores are separated from the quencher molecules and fluorescence is emitted. The amount of fluorescence detected in the optical channels is directly proportional to the quantity of the corresponding probe that is hydrolyzed. The BD MAX System monitors these signals at each cycle of the PCR and interprets the data at the end of the reaction to provide qualitative test results for each analyte.

## REAGENTS AND MATERIALS

REF	Contents	Quantity
445003-01	<b>BD MAX™ ExK TNA-3 Sample Buffer Tube</b> (with 25 septum caps)	24
	<b>BD MAX™ TNA Unitized Reagent Strip (TNA)</b> Unitized Reagent Strip containing all liquid reagents and disposable pipette tips necessary for specimen processing and TNA extraction.	
	<b>BD MAX™ ExK™ TNA Extraction Tube (B4)</b> Dried extraction reagent containing magnetic affinity beads and Proteinase K.	24 (2 x 12 tubes)
	<b>BD SARS-CoV-2 Reagents for BD MAX™ System Primers and Probes</b> Dried primers and probes for SARS-CoV-2	
	<b>BD MAX™ TNA MMK (C3)</b> Dried PCR Master Mix containing dNTPs and RT-polymerase	

## EQUIPMENT AND MATERIALS REQUIRED BUT NOT PROVIDED

- BD MAX System (BD Cat. No. 441916)
- BD MAX Sample Rack (BD Cat. No. 441935, 443550, 443551, 444807, or 444808)
- BD MAX PCR Cartridges (BD Cat. No. 437519)
- SARS CoV-2 and RNase P Controls
- Copan UTM Collection Kit
- BD UVT Collection Kit
- 0.85% Saline
- Vortex Genie 2 (VWR Cat. No. 58815-235 or equivalent)
- Multi-Tube Vortex Mixer (VWR Cat. No. 58816-115 or equivalent)
- Rack compatible with a multi-tube vortexer (e.g., Cryogenic Vial Holder or equivalent)
- Variable Volume Calibrated Pipettor (750 µL volume capable)
- Aerosol resistant micropipette tips
- Disposable gloves, powderless

## WARNINGS AND PRECAUTIONS

### Danger



**H311** Toxic in contact with skin.

**H315** Causes skin irritation.

**H317** May cause an allergic skin reaction.

**H319** Causes serious eye irritation.



**H334** May cause allergy or asthma symptoms or breathing difficulties if inhaled.

**H335** May cause respiratory irritation.

**H350** May cause cancer.

**H360** May damage fertility or the unborn child.



**H411** Toxic to aquatic life with long lasting effects.

**P201** Obtain special instructions before use.

**P202** Do not handle until all safety precautions have been read and understood.

**P233** Keep container tightly closed.



**P261** Avoid breathing dust/fume/gas/mist/vapors/spray.

**P264** Wash thoroughly after handling.

**P271** Use only outdoors or in a well-ventilated area.

**P272** Contaminated work clothing should not be allowed out of the work place.

**P273** Avoid release to the environment.

**P280** Wear protective gloves/protective clothing/eye protection/face protection.

**P281** Use personal protective equipment as required.

**P284** [In case of inadequate ventilation] wear respiratory protection.

**P308+P313** IF exposed or concerned: Get medical advice/attention.

**P332+P313** IF skin irritation occurs: Get medical advice/attention.

**P333+P313** IF skin irritation or rash occurs: Get medical advice/attention.

**P337+P313** IF eye irritation persists: Get medical advice/attention.

**P305+P351+P338** IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

**P302+P352** IF ON SKIN: Wash with plenty of water.

**P312** Call a POISON CENTER/doctor if you feel unwell.

**P321** Specific treatment.

**P342+P311** If experiencing respiratory symptoms: Call a POISON CENTER/doctor/...

**P304+P340** IF INHALED: Remove person to fresh air and keep comfortable for breathing.

**P361+P362** Take off contaminated clothing.

**P363** Wash contaminated clothing before reuse.

**P391** Collect spillage.

**P403** Store in a well-ventilated place.

**P405** Store locked up.

**P501** Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.

- For *in vitro* diagnostic use under Emergency Use Authorization only.
- For Prescription Use only.
- The BD SARS-CoV-2 Reagents for BD MAX System has not been FDA cleared or approved; the test has been authorized by FDA under an Emergency Use Authorization (EUA) for use by laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988, 42 U.S.C. 263a, that meet requirements to perform moderate or high complexity tests.
- The BD SARS-CoV-2 Reagents for BD MAX System has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The BD SARS-CoV-2 Reagents for BD MAX System is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of *in vitro* diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
- Positive results are indicative of the presence of SARS-CoV-2 RNA.
- Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities.
- All patient samples should be handled as if infectious, using good laboratory procedures as outlined in the CLSI Document M29-A4<sup>1</sup> and in Biosafety in Microbiological and Biomedical Laboratories.<sup>2</sup> Only personnel proficient in handling infectious materials and the use of BD SARS-CoV-2 and BD MAX System should perform this procedure.
- All human-sourced materials should be considered potentially infectious and should be handled with universal precautions. If spillage occurs, follow appropriate site procedures.

- Closely follow procedures and guidelines provided to ensure that the test is performed correctly. Any deviation from the procedures and guidelines may affect optimal test performance.
- Do not use expired reagents and/or materials.
- Do not use the kit if the label that seals the outer box is broken upon arrival.
- Do not use reagents if the protective pouches are open or broken upon arrival.
- Do not use reagents if desiccant is not present or broken inside reagent pouches.
- Do not remove desiccant from reagent pouches.
- Close protective pouches of reagents promptly with the zip seal after each use. Remove any excess air in the pouches prior to sealing.
- Protect reagents against heat and humidity. Prolonged exposure to humidity may affect product performance.
- Do not use reagents if the foil has been broken or damaged.
- Do not mix reagents from different pouches and/or kits and/or lots.
- Do not interchange or re-use caps, as contamination may occur and compromise test results.
- Check Unitized Reagent Strips for proper liquid fills (ensure that the liquids are at the bottom of the tubes).
- Check Unitized Reagent Strips to ensure that all pipette tips are present.
- Proceed with caution when using chemical solutions, as Extraction Tube barcode readability may be altered.
- Good laboratory technique is essential to the proper performance of this assay. Extreme care should be taken to preserve the purity of all materials and reagents.
- In cases where other PCR tests are conducted in the same general area of the laboratory, care must be taken to ensure that the BD SARS-CoV-2 components, any additional reagents required for testing, and the BD MAX System are not contaminated. Avoid microbial and ribonuclease (RNase)/deoxyribonuclease (DNase) contamination of reagents at all times. The use of sterile RNase/DNase-free disposable aerosol resistant or positive displacement pipette tips is recommended. Use a new tip for each specimen. Gloves must be changed before manipulating reagents and cartridges.
- To avoid contamination of the environment by amplicons, do not break apart the BD MAX PCR Cartridge after use. The seals of the BD MAX PCR Cartridges are designed to prevent contamination.
- The laboratory should routinely perform environmental monitoring to minimize the risk of cross-contamination.
- Wear protective clothing and disposable gloves while handling all reagents.
- Wash hands thoroughly after performing the test.
- Do not pipette by mouth.
- Do not smoke, drink, chew or eat in areas where specimens or kit reagents are being handled.
- Dispose of unused reagents and waste in accordance with local, state, provincial and/or federal regulations.
- Consult the BD MAX System User's Manual<sup>3</sup> for additional warnings, precautions and procedures.

## **STORAGE**

- BD SARS-CoV-2 Reagents for BD MAX System kit ships at ambient temperature and is stable at 2–25 °C through the stated expiration date. Do not use if expired.
- The BD MAX TNA Extraction Tubes (B4), BD MAX TNA MMK (C3), and BD SARS-CoV-2 Reagents for BD MAX System Primers and Probes are provided in sealed pouches. To protect from humidity, immediately re-seal after opening.

## **INSTRUCTIONS FOR USE**

### **Swab Specimen Collection/Transport in Universal Viral Transport (UVT) or Universal Transport Medium (UTM)**

**Note: Wear gloves when handling specimens. If gloves come in contact with the specimen, immediately change them to prevent contamination of other specimens.**

1. Nasal, nasopharyngeal, or oropharyngeal swab specimens should be collected and expressed directly into the BD Universal Viral Transport System or the Copan Universal Transport Media System according to their respective package insert instructions.
2. Transport the UVT/UTM specimen according to the manufacturer's instructions for use.

### **Swab Specimen Collection/Transport in Saline**

**Note: Wear gloves when handling specimens. If gloves come in contact with the specimen, immediately change them to prevent contamination of other specimens.**

1. Nasal swab specimens should be collected and expressed directly into the saline tube.
2. Store specimens at 2–8 °C for up to 72 hours after collection. If a delay in testing or shipping is expected, store specimens at -70°C or below.

**Note: Sample stability when using BD SARS-CoV-2 Reagents for BD MAX System has not been established for suggested temperatures and time but is based on CDC guidelines.<sup>4</sup>**

**BD MAX Sample Buffer Tube Preparation for use with nasal, nasopharyngeal, or oropharyngeal swab specimens in Universal Viral Transport (UVT) or Universal Transport Media (UTM) or nasal swab specimens in 0.85% saline**

**Note: Wear gloves when handling specimens. If gloves come in contact with the specimen, immediately change them to prevent contamination of other specimens.**

**Note: If frozen, allow Universal Viral Transport (UVT) or Universal Transport Media (UTM) specimen to come to room temperature before proceeding.**

1. Uncap the BD MAX TNA-3 Sample Buffer Tube and transfer (using a calibrated, variable pipette) 750 µL from the UVT/UTM or saline specimen directly into the BD MAX TNA-3 Sample Buffer Tube.
2. Recap the tube with a blue septum cap and vortex or mix by inversion 5 times.
3. Label the BD MAX TNA-3 Sample Buffer Tube with patient information.


**Note: Do not obscure the barcodes on the tube. Obscuring the barcode may result in BD MAX System catalog failure and inability to test the sample.**

4. Repeat Steps 1 to 3 for each UVT/UTM or saline sample that will be tested on the BD MAX System.
5. Proceed directly with the BD MAX System Operation.

#### BD MAX System Operation

**Note: Refer to the BD MAX System User's Manual<sup>3</sup> for detailed instructions (Operation section).**

1. Power on the BD MAX System (if not already done) and log in by entering <user name> and <password>.
2. Gloves must be changed before manipulating reagents and cartridges.
3. Remove the required number of TNA Unitized Reagent Strips from the BD SARS-CoV-2 Reagents for BD MAX System kit. Gently tap each Unitized Reagent Strip onto a hard surface to ensure that all the liquids are at the bottom of the tubes. Remove the required number of Extraction Tube(s) from the protective pouch. Remove excess air, and close pouches with the zip seal.
4. From the BD SARS-CoV-2 Reagents for BD MAX System kit, remove the required number of BD MAX TNA MMK Master Mix Tube(s) and BD SARS-CoV-2 Reagents for BD MAX System Primers and Probes Tube(s) from their protective pouches. Remove excess air, and close each pouch with the zip seal.
5. For each specimen to be tested, place one (1) Unitized Reagent Strip on the BD MAX System Rack. Assemble the strip as in Figure 1:



**Figure 1: Snap Extraction Tubes and Master Mix Tube into Unitized Reagent Strips**

**Note: Failure to add extraction tube or master mix tubes may result in instrument contamination.**

**Note: A conical snap-in tube is fully seated in the strip when a 'click' is heard. Refer to above for reagent placement in the Unitized Reagent Strip.**

- Position 1= Snap the BD MAX ExK TNA-3 Extraction Tube into Position 1.
  - Position 2= Snap the BD MAX TNA MMK Master Mix Tube into Position 2.
  - Position 3= Snap the BD SARS-CoV-2 Reagents for BD MAX System Primers and Probes into Position 3.
  - Position 4= Leave Position 4 empty (no conical snap-in tube).
6. Create the User Defined Protocol (UDP) as follows:
    - Navigate to Run > Test Editor tab.
    - Click "Create".
    - Complete each section of the user protocol as outlined in the screen shots below.

## Basic Information Section

Run > Test Editor > Edit > Basic Information

Test Name: BD SARS-CoV-2 TNA3T1 Extraction Type: ExK TNA-3 Master Mix Format: Type 1: BD MMK or MMK (SPC) and Dried Primers and Probes

Sample Extraction Parameters

☒ User Defined ☒ Liquid Level Sensing

Parameter	Value	Default	Value Range
Lysis Heat Time	10	10	0 - 30, ± 1 mins
Lysis Temperature	60	60	30 - 80, ± 1 °C
Sample Tip Height	1600	1600	1200 - 1600, ± 1 steps
Sample Volume	600	937.5	250 - 950, ± 2.5 µL
Wash Volume	500	500	187.5 - 500, ± 2.5 µL
Neutralization Volume	12.5	12.5	12.5 - 47.5, ± 2.5 µL
DNase Heat Time	--	--	--

Ct Calculation

☐ Call Ct at Inflection Point

☐ Call Ct at Threshold Crossing

☒ Call Ct at Threshold Crossing with Secondary QC Threshold

Custom Barcodes

Snap-In 2 Barcode: Snap-In 3 Barcode: Snap-In 4 Barcode:

Notes

0/255 characters used

Save Cancel

Back to Test List

Basic Information

PCR Settings

Melt Settings

Test Steps

Result Logic

Worklist PCR Only Test Editor Inventory

BD Log Out Unlock Door Start Run Status Results Configuration Reports Maintenance

## PCR Setting Section

Run > Test Editor > Edit > PCR Settings

Test Name: BD SARS-CoV-2 TNA3T1 Extraction Type: ExK TNA-3 Master Mix Format: Type 1: BD MMK or MMK (SPC) and Dried Primers and Probes

PCR Settings

Channel	Wavelength	Alias	PCR Gain	Threshold (Cross)	Ct Min	Ct Max	Send to LIS
Channel	475/520	N1	30	90	0	42	<input type="checkbox"/>
	530/565		0	0	0	0	<input type="checkbox"/>
	585/630	RnaseP	80	100	0	35	<input type="checkbox"/>
	630/665	N2	50	80	0	42	<input type="checkbox"/>
	680/715		0	0	0	0	<input type="checkbox"/>

Color Compensation

Excitation Channel	Wavelength	475/520	530/565	585/630	630/665	680/715
Excitation Channel	475/520	--	0	0	0	0
	530/565	0	--	0	0	0
	585/630	0	0	--	1.5	0
	630/665	0	0	0	--	0
	680/715	0	0	0	0	--

Save Cancel

Back to Test List

Basic Information

PCR Settings

Melt Settings

Test Steps

Result Logic

Worklist PCR Only Test Editor Inventory

BD Log Out Unlock Door Start Run Status Results Configuration Reports Maintenance

## Melt Settings Section

Run > Test Editor > Edit > Melt Settings

Test Name: BD SARS-CoV-2 TNA3T1 Extraction Type: ExK TNA-3 Master Mix Format: Type 1: BD MMK or MMK (SPC) and Dried Primers and Probes

3/25/2020 5:03:15 AM Instrument: 1 User: ADMIN

**Melt Settings**

Channel	Wavelength	Alias	Melt Gain	Peak Direction	Sensitivity	Melt Bins
Channel	475/520	N1	- 0 +	Peak	Medium	Edit Melt Bins
	530/565		- 0 +	Peak	Medium	Edit Melt Bins
	585/630	RnaseP	- 0 +	Peak	Medium	Edit Melt Bins
	630/665	N2	- 0 +	Peak	Medium	Edit Melt Bins
	680/715		- 0 +	Peak	Medium	Edit Melt Bins

**Color Compensation**

Excitation Channel	Wavelength	475/520	530/565	585/630	630/665	680/715
Excitation Channel	475/520	--	- 0 +	- 0 +	- 0 +	- 0 +
	530/565	- 0 +	--	- 0 +	- 0 +	- 0 +
	585/630	- 0 +	- 0 +	--	- 0 +	- 0 +
	630/665	- 0 +	- 0 +	- 0 +	--	- 0 +
	680/715	- 0 +	- 0 +	- 0 +	- 0 +	--

Save Cancel

Back to Test List

Worklist PCR Only Test Editor Inventory

BD Log Out Unlock Door Start Run Status Results Configuration Reports Maintenance

## Test Steps Section

Run > Test Editor > Edit > Test Steps

Test Name: BD SARS-CoV-2 TNA3T1 Extraction Type: ExK TNA-3 Master Mix Format: Type 1: BD MMK or MMK (SPC) and Dried Primers and Probes

3/25/2020 5:03:17 AM Instrument: 1 User: ADMIN

**Test Steps**

Step Name: Activation / RT

Profile Type: 3 - Temperature Cycles: 1

Type	Time (s)	Temp (°C)	Detect
	300	85	
	1200	58	
	120	95	

Move Add

Step Name: PCR

Profile Type: 2 - Temperature Cycles: 45

Type	Time (s)	Temp (°C)	Detect
	5	95	
	40.3	58	✓

Move Add

Save Cancel

Back to Test List

Worklist PCR Only Test Editor Inventory

BD Log Out Unlock Door Start Run Status Results Configuration Reports Maintenance

Result Logic Section (enter result logic by clicking the “Edit Logic” button)

Run > Test Editor > Edit > Result Logic

Test Name: BD SARS-CoV-2 TNA3T1 Extraction Type: ExK TNA-3 Master Mix Format: Type 1: BD MMK or MMK (SPC) and Dried Primers and Probes

Result Logic Steps

Target: CoV-2

Master Mix:

Wavelength	Alias	Type	Analyze
475/520	N1	PCR	<input checked="" type="checkbox"/>
585/630	RnaseP	PCR	<input checked="" type="checkbox"/>
630/665	N2	PCR	<input checked="" type="checkbox"/>

Edit Logic

← Move → Add +

Target: N1

Master Mix:

Wavelength	Alias	Type	Analyze
475/520	N1	PCR	<input checked="" type="checkbox"/>
585/630	RnaseP	PCR	<input checked="" type="checkbox"/>
630/665	N2	PCR	<input type="checkbox"/>

Edit Logic

← Move → Add +

Target: N2

Master Mix:

Wavelength	Alias	Type	Analyze
585/630	RnaseP	PCR	<input checked="" type="checkbox"/>
630/665	N2	PCR	<input checked="" type="checkbox"/>
475/520	N1	PCR	<input type="checkbox"/>

Edit Logic

← Move → Add +

Save Cancel

Back to Test List

Basic Information PCR Settings Melt Settings Test Steps Result Logic

Worklist PCR Only Test Editor Inventory

BD Log Out Unlock Door Start Run Status Results Configuration Reports Maintenance

Edit Logic

Target: CoV-2

Result	N1 (475/520) PCR	RnaseP (585/630) PCR	N2 (630/665) PCR
POS	Valid	Valid	Valid
POS	Valid	Valid	Invalid
POS	Valid	Invalid	Valid
POS	Valid	Invalid	Invalid
POS	Invalid	Valid	Valid
NEG	Invalid	Valid	Invalid
POS	Invalid	Invalid	Valid
UNR	Invalid	Invalid	Invalid

OK

Edit Logic

Target: N1

Result	N1 (475/520) PCR	RnaseP (585/630) PCR
POS	Valid	Valid
POS	Valid	Invalid
NEG	Invalid	Valid
UNR	Invalid	Invalid

OK

Edit Logic

Target: N2

Result	RnaseP (585/630) PCR	N2 (630/665) PCR
POS	Valid	Valid
NEG	Valid	Invalid
POS	Invalid	Valid
UNR	Invalid	Invalid

OK



Run > Test Editor > Edit > Result Logic

Test Name: BD SARS-CoV-2 TNA3T1 Extraction Type: ExK TNA-3 Master Mix Format: Type 1: BD MMK or MMK (SPC) and Dried Primers and Probes

Result Logic Steps

Target: N1

Master Mix:  

Wavelength	Alias	Type	Analyze
475/520	N1	PCR	<input checked="" type="checkbox"/>
585/630	RnaseP	PCR	<input checked="" type="checkbox"/>
630/665	N2	PCR	<input type="checkbox"/>

Edit Logic

← Move → Add +

Target: N2

Master Mix:  

Wavelength	Alias	Type	Analyze
585/630	RnaseP	PCR	<input checked="" type="checkbox"/>
630/665	N2	PCR	<input checked="" type="checkbox"/>
475/520	N1	PCR	<input type="checkbox"/>

Edit Logic

← Move → Add +

Target: RNaseP

Master Mix:  

Wavelength	Alias	Type	Analyze
585/630	RnaseP	PCR	<input checked="" type="checkbox"/>
475/520	N1	PCR	<input type="checkbox"/>
630/665	N2	PCR	<input type="checkbox"/>

Edit Logic

← Move → Add +

Save Cancel

Back to Test List

Worklist PCR Only Test Editor Inventory

BD Log Out Unlock Door Start Run Status Results Configuration Reports Maintenance

**Note:** Click on the scroll bar to scroll right.

Edit Logic

Target: RNaseP

Result	RnaseP (585/630) PCR
POS	Valid
NEG	Invalid

OK


7. Click **<SAVE>** after all information has been entered into the Test Editor. The UDP only needs to be created once, and steps 6 and 7 do not need to be repeated for subsequent runs.
8. Click on the Run tab, then Inventory. Enter the kit lot number for the BD SARS-CoV-2 Reagents for BD MAX System kit in the barcode field (for lot traceability) by either scanning the barcode with the scanner or by manual entry and then save.  
**Note: Repeat step 8 each time a new kit lot is used.**
9. Navigate to the Worklist (RUN > WORKLIST). Using the pull down menu select the UDP previously created in Step 6 (example: BD SARS-CoV-2 TNA3).
10. Enter the Sample Buffer Tube ID, Patient ID and Accession Number (if applicable) into the Worklist, either by scanning the barcode with the scanner or by manual entry.
11. Select the appropriate kit lot number (found on the outer box) from the pull down menu.
12. Repeat Steps 9 to 11 for all remaining Sample Buffer Tubes.
13. Place the Sample Buffer Tubes into the BD MAX System Rack(s) corresponding to the Unitized Reagent Strips previously assembled.

14. Place the required number of BD MAX PCR Cartridge(s) into the BD MAX System (refer to Figure 2).



**Figure 2:** Load BD PCR Cartridges

15. Load rack(s) onto the BD MAX System (refer to Figure 3).



**Figure 3:** Load Rack(s) onto the BD MAX System

16. Close the BD MAX System lid and click **<Start>** to begin the processing.

#### **QUALITY CONTROL**

Quality control procedures monitor the performance of the assay. Laboratories must establish the number, type, and frequency of testing of control materials according to guidelines or requirements of local, provincial, state, and federal and/or country regulations or accreditation organizations in order to monitor the effectiveness of the entire analytical process. For general Quality Control guidance, the user may wish to refer to CLSI MM3 and EP12.<sup>1,2</sup>

External Control materials are not provided by BD. External Positive and Negative Controls are not used by the BD MAX System software for the purpose of sample test result interpretation. External Controls are treated as if they were patient samples. (Refer to the table in the Results Interpretation section for the interpretation of External Control assay results.)

It is recommended that one (1) External Positive Control and one (1) External Negative Control be run at least daily until adequate process validation is achieved on the BD MAX System in each laboratory setting. All test controls should be examined prior to interpretation of patient results. If the controls are not valid, the patient results cannot be interpreted. Reduced frequency of control testing should be in accordance with applicable regulations.

The External Positive Control is intended to monitor for substantial reagent failure. The External Negative Control is intended to detect reagent or environmental contamination (or carry-over) by target nucleic acids.

Various types of External Controls are recommended to allow the user to select the most appropriate for their laboratory quality control program.

**External Negative Control:** A previously characterized sample known to be negative or a Sample Buffer Tube with RNase P positive control added. BD recommends that the External Negative Control be prepared prior to the External Positive Control in order to reduce the potential for contamination as a result of control preparation.

**External Positive Control:** Commercially available control material from Microbiologics, BioGX, CDC/IDT, or other authorized control material may be used.

For the preparation of External Control suspensions, it is recommended that RNA suspensions be prepared in the Sample Buffer Tube according to manufacturer's instructions.

All External Controls should yield the expected results (positive for External Positive Control, negative for External Negative Control).

An External Negative Control that yields a positive result is indicative of sample handling and/or contamination. An External Positive Control that yields a negative result is indicative of a specimen handling/preparation problem. Review the specimen handling/preparation technique.

An External Control that yields an Unresolved, Indeterminate or Incomplete test result is indicative of a reagent or a BD MAX System failure. Check the BD MAX System monitor for any error messages. Refer to the System Error Summary section of the BD MAX System User's Manual<sup>3</sup> for interpretation of warning and error codes. If the problem persists, use reagents from an unopened pouch or use a new assay kit.

## RESULT INTERPRETATION

Results are available on the results tab in the Results window on the BD MAX System monitor. The BD MAX System automatically interprets the test result when the SARS-CoV-2 User Defined Protocol (UDP) is used.

### External Negative and Positive Controls

If the positive or negative controls are processed in the run and do not exhibit the expected performance as described in the Control Interpretations table below, the assay may have been set up/or executed improperly, or reagent or equipment malfunction could have occurred. In this case, invalidate the run and re-test all samples in that run.

The RNase P gene serves as both a sample extraction control (EC) and an internal amplification control (IAC). In the event that both N1 and N2 region results are negative, an RNase P result must be positive for the BD SARS-CoV-2 result to be a valid negative result. When either N1 or N2 target result is positive, the RNase P result is ignored.

If any of the above controls do not exhibit the expected performance as described, the assay may have been set up/or executed improperly, or reagent or equipment malfunction could have occurred. Invalidate the run and re-test.

**Table 1: External Control Expected Results**

Control Type		Used to Monitor	Expected Results			
			N1	N2	RNase P	CoV-2
External Negative Control	Known Negative Sample	Reagent and/or environmental contamination and reagent failure including primer and probe integrity	NEG	NEG	POS	NEG
	RNase P Positive Control		NEG	NEG	POS	NEG
External Positive Control	N1 and N2 Positive Control	Substantial reagent failure including primer and probe integrity	POS	POS	N/A	POS

### Examination and Interpretation of Patient Specimen Results

Assessment of clinical specimen test results should be performed after the external positive and negative controls have been examined and determined to be valid and acceptable. If the controls are not valid, the patient results cannot be interpreted.

The table below lists the expected results. If results are obtained that do not follow these guidelines, re-extract and re-test the sample. If repeat testing yields similar results, collect a fresh sample from the patient for testing.

**Table 2: Interpretation of Patient Specimen Results**

N1 Region	N2 Region	Extraction Control (RNase P)	CoV-2	Result Interpretation <sup>a,b</sup>	Actions
POS	POS	POS/NEG	POS	Positive	Report as Presumptive Positive <sup>c</sup>
POS	NEG/UNR	POS/NEG	POS	Positive	Report as Presumptive Positive <sup>c</sup>
NEG/UNR	POS	POS/NEG	POS	Positive	Report as Presumptive Positive <sup>c</sup>
NEG	NEG	POS	NEG	Negative	Report as Not Detected
UNR	UNR	NEG	UNR	UNR	Repeat Test <sup>d</sup>

<sup>a</sup>UNR = Unresolved

<sup>b</sup>Laboratories should report their diagnostic result as appropriate and in compliance with their specific reporting system.

<sup>c</sup>Positive results should be treated as presumptive and tested with an alternative FDA authorized molecular assay.

<sup>d</sup>Repeat Test by preparing a fresh Sample Buffer Tube from the original primary sample.

## UNRESOLVED, INDETERMINATE, AND INCOMPLETE RESULTS

When an Indeterminate (IND), Unresolved (UNR), or Incomplete (INC) result is obtained a repeat test from the primary sample must be performed. If an External Control fails, repeat testing of all specimens conducted on the same day using freshly prepared External Controls (see Quality Control).

### Unresolved Result

Unresolved results may be obtained in the event that specimen-associated inhibition or reagent failure prevents proper target or RNase P amplification. Sample(s) can be repeated from the primary sample. Uncap the BD MAX TNA-3 Sample Buffer Tube and transfer (using a calibrated, variable pipette) 750 µL from the UVT/UTM/saline specimen directly into the BD MAX TNA-3 Sample Buffer Tube. Restart from the BD MAX System Operation section.

### Indeterminate Result

Indeterminate results may be obtained in the event that a System failure occurs. Sample(s) can be repeated from the primary sample. Uncap the BD MAX TNA-3 Sample Buffer Tube and transfer (using a calibrated, variable pipette) 750 µL from the UVT/UTM/saline specimen directly into the BD MAX TNA-3 Sample Buffer Tube. Restart from the BD MAX System Operation section.

### Incomplete Result

Incomplete results may be obtained in the event that Specimen Preparation or the PCR did not reach its expected time points. Sample(s) can be repeated from the primary sample. Uncap the BD MAX TNA-3 Sample Buffer Tube and transfer (using a calibrated, variable pipette) 750 µL from the UVT/UTM/saline specimen directly into the BD MAX TNA-3 Sample Buffer Tube. Restart from the BD MAX System Operation section.

### External Control Failure

External Controls should yield expected results when tested. If samples have to be repeated due to an incorrect External Control result, the samples should be repeated from the primary sample along with freshly prepared External Controls. Restart from the BD MAX System Operation section.

## LIMITATIONS OF THE PROCEDURE

- BD SARS-CoV-2 Reagents for BD MAX System has been evaluated only for use on the BD MAX System.
- Reliable results depend on proper sample collection, storage and handling procedures.
- This test has been designed for the detection of SARS-CoV-2 RNA in nasopharyngeal, oropharyngeal, and nasal swab samples collected in BD Universal Viral Transport System (UVT) or Copan Universal Transport Media System (UTM) and nasal swabs collected in 0.85% saline (self-collected under supervision of a healthcare provider or healthcare provider-collected). BD SARS-CoV-2 Reagents for BD MAX System performance was evaluated using nasopharyngeal and nasal swabs. Use of BD SARS-CoV-2 Reagents for BD MAX System with other sample types, including nasopharyngeal wash/aspirate, nasal aspirates, mid-turbinate nasal swabs (self-collected under supervision of or collected by a healthcare provider), and oropharyngeal swabs are acceptable, however, performance characteristics are unknown.
- Positive results should be treated as presumptive and tested with an alternative FDA authorized molecular assay.
- Detection of SARS-CoV-2 RNA may be affected by sample collection methods, patient factors (e.g., presence of symptoms), and/or stage of infection.
- As with any molecular test, mutations within the target regions of SARS-CoV-2 could affect primer and/or probe binding resulting in failure to detect the presence of virus.
- Due to inherent differences between technologies, it is recommended that, prior to switching from one technology to the next, users perform method correlation studies in their laboratory to qualify technology differences. One hundred percent agreement between the results should not be expected due to aforementioned differences between technologies. Users should follow their own specific policies/procedures.
- False negative or invalid results may occur due to interference. The RNase P endogenous control is included to help identify the specimens containing substances that may interfere with nucleic acid isolation and PCR amplification.
- Good laboratory practices and careful adherence to the procedures specified in this Instructions For Use document are necessary to avoid contamination of reagents.
- For BD MAX TNA extraction: Tobramycin at  $1.1 \times 10^{-3}$  g/Sample Buffer Tube interferes with the assay. Lower concentrations of Tobramycin have not been evaluated.
- The effect of homeopathic medications for respiratory symptoms on the assay performance was not tested.
- BD SARS-CoV-2 Reagents have not been evaluated for patients receiving intranasally administered influenza vaccine.
- This test has not been FDA cleared or approved.
- This test has been authorized by FDA under an EUA for use by authorized laboratories.
- This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens.
- This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of *in vitro* diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

## CONDITIONS OF AUTHORIZATION FOR THE LABORATORY

The BD SARS-CoV-2 Reagents for BD MAX System Letter of Authorization, along with the authorized Fact Sheet for Healthcare Providers, the authorized Fact Sheet for Patients, and authorized labeling are available on the FDA website:

<https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations-medical-devices>

To assist clinical laboratories running the BD SARS-CoV-2 Reagents for BD MAX System, the relevant Conditions of Authorization are listed below, and are required to be met by laboratories performing the EUA test.

- Authorized laboratories\* using the BD SARS-CoV-2 Reagents for BD MAX System will include with result reports of the BD SARS-CoV-2 for BD MAX System test, all authorized Fact Sheets. Under exigent circumstances, other appropriate methods for disseminating these Fact Sheets may be used, which may include mass media.
- Authorized laboratories using the BD SARS-CoV-2 Reagents for BD MAX System will perform the BD SARS-CoV-2 Reagents for use with the BD MAX System as outlined in the BD SARS-CoV-2 Reagents for BD MAX System Instructions for Use. Deviations from the authorized procedures, including the authorized instruments, authorized extraction methods, authorized clinical specimen types, authorized control materials, authorized ancillary reagents, and authorized material required to perform the BD SARS-CoV-2 Reagents for BD MAX System test are not permitted.
- Authorized laboratories that receive the BD SARS-CoV-2 Reagents for BD MAX System test must notify the relevant public health authorities of their intent to run the test prior to initiating testing.
- All laboratory personnel using the BD SARS-CoV-2 Reagents for BD MAX System test must be appropriately trained in RT-PCR techniques, use appropriate laboratory and personal protective equipment when handling this kit, and use the test in accordance with the authorized labeling.
- Authorized laboratories using the BD SARS-CoV-2 Reagents for BD MAX System test will have a process in place for reporting test results to healthcare providers and relevant public health authorities, as appropriate.
- Becton, Dickinson and Company, authorized distributors, and authorized laboratories using the BD SARS-CoV-2 Reagents for BD MAX System will ensure that any records associated with this EUA are maintained until otherwise notified by FDA. Such records will be made available to FDA for inspection upon request.
- Authorized laboratories will collect information on the performance of the BD SARS-CoV-2 Reagents for BD MAX System test and report to DMD/OHT7-OIR/OPEQ/ CDRH (via email: [CDRH-EUA-Reporting@fda.hhs.gov](mailto:CDRH-EUA-Reporting@fda.hhs.gov)) and to Becton, Dickinson and Company Customer Technical Support 1.800.638.8663 any suspected occurrence of false positive or false negative results and significant deviations from the established performance characteristics of the BD SARS-CoV-2 Reagents for BD MAX System test of which they become aware.

\*For ease of reference, the letter of authorization refers to, "Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet requirements to perform moderate or high complexity tests" as "authorized laboratories".

## NON-CLINICAL PERFORMANCE EVALUATION

### Limit of Detection (LoD)

LoD studies determine the lowest detectable concentration of the SARS-CoV-2 at which approximately 95% of all (true positive) replicates test positive.

To determine the LoD, quantified heat-inactivated virus, obtained from ATCC® (Cat. No. VR-1986HK) was serially diluted into pooled negative nasopharyngeal clinical matrix, a total of 5 concentrations levels, with 2-fold serial dilutions between each level.

Confirmation of the estimated LoD was performed with one reagent lot in replicates of 20 prepared in pooled nasopharyngeal swab clinical matrix. The LoD is the lowest concentration (reported as genomic copies/mL, GC/mL) of SARS-CoV-2 that can be reproducibly distinguished from negative samples  $\geq 95\%$ . The LoD for the assay is 640 GC/mL.

**Table 3. LoD determination of SARS-CoV-2 USA-WA1/2020 heat-inactivated virus**

Strain	Concentration	Total Valid Results	Positives			Mean Ct		
			CoV-2	N1	N2	N1	N2	RNase P
USA-WA1/2020 Heat-Inactivated Virus (Stock 3.75e+05 GC/mL)	640 GC/mL	20	20	20	20	33.2	33.2	21.0

Additionally, 20 replicates at 40 genomic equivalents/ml (GE/mL) using quantified genomic viral RNA from SARS-CoV-2 obtained from BEI Resources (Cat. No NR52285) were tested and 20 positive results were obtained.

**Table 4. Detection of quantified genomic viral RNA from SARS-CoV-2 USA-WA1/2020**

Strain	Concentration	Total Valid Results	Positives			Mean Ct		
			CoV-2	N1	N2	N1	N2	RNase P
USA-WA1/2020 Genomic RNA (Stock 4.8e+07 GE/mL)	40 GE/mL	20	20	20	20	32.2	32.6	21.5

#### Reactivity/Inclusivity

The nCoV N1 and nCoV N2 primers and probes utilized within the BD SARS-CoV-2 Reagents for BD MAX System are identical in sequence to those reported in the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel. An *in silico* comparison of the N1 and N2 primer sets was performed using all 111 available SARS-CoV-2 sequences in the NCBI nt database (Genbank) as of April 1, 2020. Multiple sequence alignment revealed 100% sequence identity (0 mismatches) across the entire 72 base-pair region of the N1 primer/probe set for all sequences. Multiple sequence alignment showed 100% sequence identity (0 mismatches) across the entire 67 base-pair region of the N2 primer/probe set with one exception. Sequence accession MT159720.1 indicates a "T" instead of a "C" at the 5' end of the N2 reverse primer. In a separate analysis on April 9, 2020, 3,634 full length SARS-Cov-2 genomes were retrieved from the GISAID EpiCoV database, only including human isolates marked as "high coverage". Multiple alignment of the N gene showed that 98.0% of the sequences were a perfect match to the N1 primer set region, and 99.5% were a perfect match to the N2 primer set region. All variants have a perfect match to either the N1 region or the N2 region primer set.

#### Cross-Reactivity

The nCoV N1 and nCoV N2 primers and probes utilized within the BD SARS-CoV-2 Reagents for BD MAX System are identical in sequence to those reported in the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel. The CDC reported an *in silico* analysis of primer and probe sequences within their IFU (CDC-006-0019, Rev 02), and has been copied below for reference:

BLASTn analysis queries of the 2019-nCoV rRT-PCR assays primers and probes were performed against public domain nucleotide sequences. The database search parameters were as follows: 1) The nucleotide collection consists of GenBank+EMBL+DDBJ+PDB+RefSeq sequences, but excludes EST, STS, GSS, WGS, TSA, patent sequences as well as phase 0, 1, and 2 HTGS sequences and sequences longer than 100Mb; 2) The database is non-redundant. Identical sequences have been merged into one entry, while preserving the accession, GI, title and taxonomy information for each entry; 3) Database was updated on 10/03/2019; 4) The search parameters automatically adjust for short input sequences and the expect threshold is 1000; 5) The match and mismatch scores are 1 and -3, respectively; 6) The penalty to create and extend a gap in an alignment is 5 and 2, respectively.

#### 2019-nCoV\_N1 Assay:

Probe sequence of 2019-nCoV rRT-PCR assay N1 showed high sequence homology with SARS coronavirus and Bat SARS-like coronavirus genome. However, forward and reverse primers showed no sequence homology with SARS coronavirus and Bat SARS-like coronavirus genome. Combining primers and probe, there is no significant homologies with human genome, other coronaviruses or human microflora that would predict potential false positive rRT-PCR results.

#### 2019-nCoV\_N2 Assay:

The forward primer sequence of 2019-nCoV rRT-PCR assay N2 showed high sequence homology to Bat SARS-like coronaviruses. The reverse primer and probe sequences showed no significant homology with human genome, other coronaviruses or human microflora. Combining primers and probe, there is no prediction of potential false positive rRT-PCR results.

In summary, the 2019-nCoV rRT-PCR assay N1 and N2, designed for the specific detection of 2019-nCoV, showed no significant combined homologies with human genome, other coronaviruses, or human microflora that would predict potential false positive rRT-PCR results.

#### CLINICAL EVALUATION

The clinical performance of BD SARS-CoV-2 Reagents for BD MAX System with retrospective collected nasopharyngeal swab samples was evaluated using 100 individual negative clinical samples and 30 positive clinical samples as determined by an FDA-authorized SARS-CoV-2 molecular assay. Clinical samples were collected from patients suspected of COVID-19 by their healthcare provider and tested in blinded and randomized fashion.

The positive samples showed 100% agreement with the expected results. The negative samples showed 97% agreement with the expected results.



**Table 5. Clinical Comparison with an FDA-authorized molecular assay**

		FDA-authorized molecular assay	
		Positive	Negative
BD SARS-CoV-2 Reagents	Positive	30	3
	Negative	0	97
	Total	30	100
Positive Percent Agreement:		100% (95% CI: 88.7%–100%)	
Negative Percent Agreement:		97% (95% CI: 91.5%–99.0%)	

The performance of BD SARS-CoV-2 Reagents for BD MAX System was further evaluated using 20 contrived positive clinical samples prepared in negative nasopharyngeal matrix. Low positive contrived clinical samples were prepared by spiking quantified heat-inactivated virus (USA-WA1/2020 strain) into individual negative clinical matrix to approximately 2x LoD. The low positive samples showed 100% agreement with the expected results.

**Table 6. Clinical Evaluation with Contrived Nasopharyngeal Swab Samples**

Concentration	Total Valid Results	Positive			Mean Ct		
		CoV-2	N1	N2	N1	N2	RNase P
2x LoD	20	20	20	20	32.1	32.0	23.2

The performance of BD SARS-CoV-2 Reagents for BD MAX System with nasal swab matrix expressed in UVT or 0.85% saline was evaluated using 15 contrived positive samples and 5 negative samples prepared in negative nasal clinical matrix.

Low positive and moderate positive contrived clinical samples were prepared by spiking quantified heat-inactivated virus (USA-WA1/2020 strain) into individual negative clinical matrix at concentrations of 2x LoD (10 samples) and 5x LoD (5 samples), respectively. The low positive, moderate positive, and negative samples showed 100% agreement with the expected results.

**Table 7. Clinical Evaluation with Contrived Nasal Swab Samples**

Sample Type	Sample Concentration	Positive			Mean Ct		
		SARS-CoV-2	N1	N2	N1	N2	RNase P
UVT	Negative	0% (0/5)	0% (0/5)	0% (0/5)	N/A	N/A	24.6
	Low Positive (2x)	100% (10/10)	100% (10/10)	100% (10/10)	31.8	32.0	24.9
	Moderate Positive (5x)	100% (5/5)*	100% (5/5)	100% (5/5)	30.5	30.6	23.9
Saline	Negative	0% (0/5)	0% (0/5)	0% (0/5)	N/A	N/A	25.5
	Low Positive (2x)	100% (10/10)	100% (10/10)	100% (10/10)	32.4	32.9	26.3
	Moderate Positive (5x)	100% (5/5)	100% (5/5)	100% (5/5)	30.9	31.6	26.0

\*One invalid result was obtained during initial testing. The expected result was obtained upon re-test of the sample.

### FDA SARS-CoV-2 REFERENCE PANEL TESTING

The evaluation of sensitivity and MERS-CoV cross-reactivity was performed using reference material (T1), blinded samples, and a standard protocol provided by the FDA. The study included a range-finding study and a confirmatory study for LoD. Blinded sample testing was used to establish specificity and to confirm the LoD. The extraction method and instrument used were the BD MAX System. The results are summarized in Table 8.

**Table 8. Summary of LoD confirmation result using the FDA SARS-CoV-2 reference panel**

Reference Materials Provided by FDA	Specimen Type	Product LoD	Cross-Reactivity
SARS-CoV-2	Nasopharyngeal matrix	5,400 NDU/mL	N/A
MERS-CoV		N/A	ND

NDU/mL = RNA NAAT detectable units/mL

N/A = Not applicable

ND = Not detected

### REFERENCES

1. Clinical and Laboratory Standards Institute. Protection of laboratory workers from occupationally acquired infections; Approved Guideline. Document M29 (refer to the latest edition).
2. Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in microbiological and biomedical laboratories. Chosewood L.C. and Wilson D.E. (eds) (2009). HHS Publication No. (CDC) 21–1112.
3. BD MAX System User's Manual (refer to the latest revision) BD Life Sciences, Sparks, MD 21152 USA.
4. Centers for Disease Control and Prevention. Interim guidelines for collecting, handling, and testing clinical specimens from persons for Coronavirus Disease 2019 (COVID-19).

## Change History

Revision	Date	Change Summary
(03)	2020-06	Addition of limitations regarding EUA authorization.
(04)	2020-09	Updated intended use statement, Updated Warnings and Precautions. Replaced screenshot in PCR Setting Section to update threshold value. Modified RNase P expected result in Table 1. Updated Table 2 reporting for positive results, added limitation for presumptive positive results. Limit of Detection section and Table 3 revised with heat inactivated virus data. Table 4 updated with new genomic RNA analytical data. Added Table 5 showing clinical comparison to an FDA-authorized molecular assay. Tables 6 and 7 were modified to update clinical evaluations with contrived clinical nasopharyngeal swab data and contrived clinical nasal swab data, respectively. Added FDA SARS-CoV-2 Reference Panel Testing section.
(05)	2020-09	Clarified CLIA statements and that all (not just positive) results must be reported to the appropriate public health authorities. Updated FDA website.



US Customers only: For symbol glossary, refer to [bd.com/symbols-glossary](http://bd.com/symbols-glossary)



Manufacturer / Производител / Výrobce / Fabrikant / Hersteller / Κατασκευαστής / Fabricante / Tootja / Fabricant / Proizvođač / Gyártó / Fabbicante / Атқарушы / 제조업체 / Gamintojas / Ražotājs / Tilvirkker / Producent / Producător / Производителъ / Výrobca / Proizvođač / Tillverkare / Üretici / Виробник / 生产厂商



Use by / Използвайте до / Spotfëbujte do / Brug før / Verwendbar bis / Χρήση έως / Usar antes de / Kasutada enne / Date de péremption / 사용 기한 / Upotrijebiti do / Felhasználhatóság dátuma / Usare entro / Дейин пайдалануға / Naudokite iki / Izlietot līdz / Houdbaar tot / Brukes for / Stosować do / Prazo de validade / A se utiliza până la / Исползовать до / Použít do / Upotrebiti do / Använd före / Son kulanma tarihi / Використати до / 使用截止日期

YYYY-MM-DD / YYYY-MM (MM = end of month)  
ГГГГ-ММ-ДД / ГГГГ-ММ (ММ = края на месеца)  
RRRR-MM-DD / RRRR-MM (MM = konec měsíce)  
AAAA-MM-DD / AAAA-MM (MM = slutning af måned)  
JJJJ-MM-TT / JJJJ-MM (MM = Monatsende)  
EEEE-MM-HH / EEEE-MM (MM = τέλος του μήνα)  
AAAA-MM-DD / AAAA-MM (MM = fin del mes)  
AAAA-KK-PP / AAAA-KK (KK = kuu lõpp)  
AAAA-MM-JJ / AAAA-MM (MM = fin du mois)  
GGGG-MM-DD / GGGG-MM (MM = kraj mjeseca)  
EEEE-HH-NN / EEEE-HH (HH = hónap utolsó napja)  
AAAA-MM-GG / AAAA-MM (MM = fine mese)  
ЖӨЖӨЖ-АА-КК / ЖӨЖӨЖ-АА / (АА = айдың соңы)  
YYYY-MM-DD/YYYY-MM (MM = 월말)  
MMMM-MM-DD / MMMM-MM (MM = mēnesio pabaiga)  
GGGG-MM-DD/GGGG-MM (MM = mēneša beigas)  
JJJJ-MM-DD / JJJJ-MM (MM = einde maand)  
AAAA-MM-DD / AAAA-MM (MM = sluttet av måneden)  
RRRR-MM-DD / RRRR-MM (MM = koniec miesiąca)  
AAAA-MM-DD / AAAA-MM (MM = fim do mês)  
AAAA-LL-ZZ / AAAA-LL (LL = sfârșitul lunii)  
ГГГГ-ММ-ДД / ГГГГ-ММ (ММ = конец месяца)  
RRRR-MM-DD / RRRR-MM (MM = koniec miesiąca)  
GGGG-MM-DD / GGGG-MM (MM = kraj mjeseca)  
AAAA-MM-DD / AAAA-MM (MM = slutet av månaden)  
YYYY-AA-GG / YYYY-AA (AA = ayın sonu)  
PPPP-MM-DD / PPPP-MM (MM = кінець місяця)  
YYYY-MM-DD / YYYY-MM (MM = 月末)



Catalog number / Каталоген номер / Katalogové číslo / Katalognummer / Αριθμός καταλόγου / Número de catálogo / Katalooginumber / Numéro catalogue / Kataloški broj / Katalogsszám / Numero di catalogo / Каталог номер / 카탈로그 번호 / Katalog / numeris / Kataloga numurs / Catalogus nummer / Numer katalogowy / Număr de catalog / Номер по каталогу / Katalogové číslo / Kataloški broj / Katalog numarası / Номер за каталогом / 目錄号



Authorized Representative in the European Community / Оторизирани представител в Европейската общност / Autorizovaný zástupce pro Evropském společenství / Autoriseret repræsentant i De Europæiske Fællesskaber / Autorisierter Vertreter in der Europäischen Gemeinschaft / Εξουσιοδοτημένος αντιπρόσωπος στην Ευρωπαϊκή Κοινότητα / Representante autorizado en la Comunidad Europea / Volitadud esindaja Euroopa Nõukogus / Représentant autorisé pour la Communauté européenne / Autorizirani predstavnik u Evropskoj uniji / Meghatalmazott képviselő az Európai Közösségekben / Rappresentante autorizzato nella Comunità Europea / Европа қауымдастығындағы уәкілетті өкіл / 유럽 공동체의 위임 대표 / Igaliotasis atstovas Europos Bendrijoje / Pilnvarotais pārstāvis Eiropas Kopienā / Bevoegde vertegenwoordiger in de Europese Gemeenschap / Autoriseret representant i EU / Autorizowane przedstawicielstwo we Wspólnocie Europejskiej / Representante autorizado na Comunidade Europeia / Reprezentantul autorizat pentru Comunitatea Europeană / Уполномоченный представитель в Европейском сообществе / Autorizovaný zástupce v Európskom spoločenstve / Autorizovano predstavništvo u Evropskoj uniji / Auktoriserad representant i Europeiska gemenskapen / Ανγυρα Τολυλугу Yetkili Təmsilçisi / Уповноважений представник у країнах ЄС / 欧洲共同体授权代表



In Vitro Diagnostic Medical Device / Медицински уред за диагностика ин витро / Lékařské zařízení určené pro diagnostiku in vitro / In vitro diagnostisk medicinsk anordning / Medizinisches In-vitro-Diagnostikum / In vitro бiяцuыткiк iтpикiк cуacкeй / Dispositivo médico para diagnóstico in vitro / In vitro diagnostika meditsiniaparatuur / Dispositif médical de diagnostic in vitro / Medicinska romagala za In Vitro Dijagnostiku / In vitro diagnosztikai orvosi eszköz / Dispositivo medicale per diagnostica in vitro / Жасанды жағдайда жүргізілетін медициналық диагностика аспабы / In Vitro Diagnostic 의료 기기 / In vitro diagnostikos prietais / Medicinas ierices, ko lieto in vitro diagnostikā / Medisch hulpmiddel voor in-vitro diagnostiek / In vitro diagnostisk medisinsk utstyr / Urządzenie medyczne do diagnostyki in vitro / Dispositivo médico para diagnóstico in vitro / Dispositiv medical pentru diagnostic in vitro / Медицинский прибор для диагностики ин витро / Medicinska romčka na diagnostiku in vitro / Medicinski uređaj za in vitro dijagnostiku / Medicinteknisk produkt för in vitro-diagnostik / In Vitro Dijagnostik Tibbi Cihaz / Медицинский прибор для диагностики ин витро / 体外诊断医疗设备



Temperature limitation / Температурни ограничения / Teplotní omezení / Temperaturbegrænsning / Temperaturbegrenzung / Περιορισμοί θερμοκρασίας / Limitación de temperatura / Temperatuuri piirang / Limites de température / Dozvoljena temperatura / Hőmérsékleti határ / Limiti di temperatura / Температураны шектеу / 온도 제한 / Laikymo temperatūra / Temperatūros ierobojojumi / Temperatuurilimiet / Temperaturbegrensning / Ograniczenie temperatury / Limites de temperatura / Limite de temperatură / Органичення температури / Ograničenje teploty / Ograničenje temperature / Temperaturgräns / Sıcaklık sınırlaması / Обмеження температури / 温度限制



Batch Code (Lot) / Код на партидата / Kód (číslo) šarže / Batch-kode (lot) / Batch-Code (Charge) / Κωδικός παρτίδας (παρτίδα) / Código de lote (lote) / Partii kood / Numéro de lot / Lot (kod) / Tétel száma (Lot) / Codice batch (lotto) / Топтама коды / 배치 코드(로트) / Partijos numeris (LOT) / Partijas kods (laidiens) / Lot number / Batch-kode (parti) / Kod parti (serie) / Código do lote / Cod de serie (Lot) / Код партии (not) / Kód série (šarža) / Kod serije / Partinummer (Lot) / Parti Kodu (Lot) / Код партии / 批号 (亚批)



Contains sufficient for <n> tests / Съдържанието е достатъчно за <n> теста / Dostatečné množství pro <n> testů / Indeholder tilstrækkeligt til <n> tests / Ausreichend für <n> Tests / Περιέχει επαρκή ποσότητα για <n> εξετάσεις / Contenido suficiente para <n> pruebas / Küllaldane <n> testide jaoks / Contenu suffisant pour <n> tests / Sadržaj za <n> testova / <n> testezhez elegendő / Contenido suficiente per <n> test / <n> тесттең үшүн жеткілікті / <n> 테스트가 충분히 포함됨 / Pakankamas kiekis atlikti <n> testų / Satur pietiekami <n> pārbaudēm / Inhoud voldoende voor "n" testen / Innholder tilstrekkelig til <n> tester / Zawiera ilość wystarczającą do <n> testów / Conteúdo suficiente para <n> testes / Conținut suficient pentru <n> teste / Достаточно для <n> тестов(a) / Obsah vystačí na <n> testov / Sadržaj dovoljan za <n> testova / Innehåller tillräckligt för <n> analyser / <n> test için yeterli miktarda içerir / Вистачить для аналізу: <n> / 足够进行 <n> 次检测



Consult Instructions for Use / Направете справка в инструкциите за употреба / Prostudujte pokyny k použití / Se brugsanvisningen / Gebrauchsanweisung beachten / Συμβουλευτείτε τις οδηγίες χρήσης / Consultar las instrucciones de uso / Lugeda kasutusjuhendit / Consulter la notice d'emploi / Koristi upute za upotrebu / Olvassa el a használati utasítást / Consultare le istruzioni per l'uso / Пайдалану нұсқаулығымен танысып алыңыз / 사용 지침 참조 / Skaitykite naudojimo instrukcijas / Skatīt lietošanas pamācību / Raadpleeg de gebruiksaanwijzing / Se i bruksanvisningen / Zobacz instrukcja użytkowania / Consultar as instruções de utilização / Consultați instrucțiunile de utilizare / См. руководство по эксплуатации / Pozri Pokyny na používanie / Pogledajte uputstvo za upotrebu / Se bruksanvisningen / Kullanım Talimatları'na başvurun / Див. інструкції з використання / 请参阅使用说明



Do not reuse / Не използвайте отново / Neponožujte opakovaně / Ikke til genbrug / Nicht wiederverwenden / Μην επαναχρησιμοποιείτε / No reutilizar / Mitte kasutada korduvalt / Ne pas réutiliser / Ne koristiti ponovo / Egyyszer használatos / Non riutilizzare / Пайдаланбаңыз / 재사용 금지 / Tik vienkartiniam naudojimui / Nelietot atkārtoti / Niet opnieuw gebruiken / Kun til engangsbruk / Nie stosować powtórnie / Não reutilize / Nu refolositi / Не использовать повторно / Neponožujte opakovane / Ne upotrebljavati ponovo / Far ej återanvändas / Tekrar kulanmayın / Не використовувати повторно / 请勿重复使用



Serial number / Серийн номер / Sériové číslo / Seriennummer / Seriennummer / Σειριακός αριθμός / N° de serie / Seerianumber / Numéro de série / Serijski broj / Sorozatszám / Numero di serie / Топталмалық нөмірі / 일련 번호 / Serijos numeris / Sérijas numurs / Serie nummer / Numer serijny / Número de série / Număr de serie / Серийный номер / Seri numarası / Номер серії / 序列号



For IVD Performance evaluation only / Само за оценка качеството на работа на IVD / Pouze pro vyhodnocení výkonu IVD / Kun til evaluering af IVD ydelse / Nur für IVD-Leistungsbewertungszwecke / Μόνο για αξιολόγηση απόδοσης IVD / Sólo para la evaluación del rendimiento en diagnóstico in vitro / Ainult IVD seadme hindamiseks / Réserve à l'évaluation des performances IVD / Samo u znanstvene svrhe za In Vitro Dijagnostiku / Kizárólag in vitro diagnosztikához / Solo per valutazione delle prestazioni IVD / Жасанды жағдайда «пробирка ішінде» диагностикада тек жұмысты бағалау үшін / IVD 성능 평가에 대해서만 사용 / Tik IVD prietaisų veikimo charakteristikoms tikrinti / Vienīgi IVD darbības novērtēšanai / Uitsluitend voor doeltreffendheidsonderzoek / Kun for evaluering av IVD-yltelse / Tylko do oceny wydajności IVD / Uso exclusivo para avaliação de IVD / Numai pentru evaluarea performanței IVD / Только для оценки качества диагностики ин витро / Určene iba na diagnostiku in vitro / Samo za procenu učinka u in vitro diagnostici / Endast för utvärdering av diagnostisk användning in vitro / Yalnızca IVD Performans değerlendirilmesi için / Тільки для оцінювання якості діагностики in vitro / 仅限 IVD 性能评估

For US: "For Investigational Use Only"



Lower limit of temperature / Доген лимит на температурата / Dolni hranice teploty / Nedre temperaturgrænse / Temperaturuntergrenze / Κατώτερο όριο θερμοκρασίας / Limite inferior de temperatura / Alumine temperatuuripiir / Limite inférieure de température / Najniža dozvoljena temperatura / Alsó hőmérsékleti határ / Limite inferiore di temperatura / Температураның төменгі рұқсат шегі / 하한 온도 / Žemiausia laikymo temperatūra / Temperatūros zemākā robeža / Laagste temperatuurilimiet / Nedre temperaturgrænse / Dolna granica temperatury / Limite mínimo de temperatura / Limită minimă de temperatură / Нижний предел температуры / Spodná hranica teploty / Donja granica temperature / Nedre temperaturgräns / Sıcaklık alt sınırı / Мінімальна температура / 温度下限

	Control / Контролно / Kontrola / Kontrol / Kontrolle / Μάρτυρας / Kontroll / Contrôle / Controllo / Бакылау / 컨트롤 / Kontrolé / Kontrolle / Controle / Controllo / Контроль / kontroll / Контроль / 对照
	Positive control / Положителен контрол / Pozitívni kontrola / Positiv kontrol / Positive Kontrolle / Θετικός μάρτυρας / Control positivo / Positiivne kontroll / Contrôle positif / Pozitívna kontrola / Pozitív kontroll / Controllo positivo / Оң бакылау / 양성 컨트롤 / Teigiama kontrolė / Pozitívá kontrola / Positiieve controle / Kontrola dodatnia / Controllo positivo / Control pozitiv / Положительный контроль / Pozitíf kontrol / Позитивний контроль / 阳性对照试剂
	Negative control / Отрицателен контрол / Negativní kontrola / Negativ kontrol / Negative Kontrolle / Αρνητικός μάρτυρας / Control negativo / Negatiivne kontroll / Contrôle négatif / Negativna kontrola / Negatív kontroll / Controllo negativo / Негативтік бакылау / 음성 컨트롤 / Neigiama kontrolė / Negatívá kontrola / Negatieve controle / Kontrola ujemna / Controllo negativo / Control negativ / Отрицательный контроль / Negatíf kontrol / Негативний контроль / 阴性对照试剂
	Method of sterilization: ethylene oxide / Метод на стерилизация: етиленов оксид / Způsob sterilizace: etylenoxid / Steriliseringsmetode: ethylenoxid / Sterilisationsmethode: Ethylenoxid / Μέθοδος αποστείρωσης: αιθυλενοξείδιο / Método de esterilización: óxido de etileno / Steriliseerimismeetod: etüleenoksiid / Méthode de stérilisation: oxyde d'éthylène / Metoda sterilizacije: etilen oksid / Sterilizálás módszere: etilén-oxid / Metoda di sterilizzazione: ossido di etilene / Стерилизация адиси – этилен тотыгы / 소독 방법: 에틸렌옥사이드 / Sterilizavimo būdas: etileno oksidas / Sterilizēšanas metode: etilēnoksīds / Gesteriliseerd met behulp van ethyleenoxide / Steriliseringsmetode: etylenoksid / Metoda sterylizacji: tlenek etylu / Método de esterilização: óxido de etileno / Metodă de sterilizare: oxid de etilenă / Метод стерилизации: этиленоксид / Metóda sterilizácie: etylenoxid / Metoda sterilizacije: etilen oksid / Steriliseringsmetod: etenoxid / Sterilizasyon yöntemi: etilen oksit / Метод стерилизації: етиленоксидом / 灭菌方法: 环氧乙烷
	Method of sterilization: irradiation / Метод на стерилизация: ирадиация / Způsob sterilizace: záření / Steriliseringsmetode: bestråling / Sterilisationsmethode: Bestrahlung / Μέθοδος αποστείρωσης: ακτινοβολία / Método de esterilización: irradiación / Steriliseerimismeetod: kiirgus / Méthode de stérilisation: irradiation / Metoda sterilizacije: zračenje / Sterilizálás módszere: besugárzás / Metoda di sterilizzazione: irradiazione / Sterilizacija: γαма-стерилизация / Sterilizavimo būdas: radiacija / Sterilizēšanas metode: apstarošana / Gesteriliseerd met behulp van bestraling / Steriliseringsmetode: bestråling / Metoda sterylizacji: napromienianie / Método de esterilização: irradiação / Metodă de sterilizare: iradiere / Метод стерилизации: облучение / Metóda sterilizácie: ožiarenie / Metoda sterilizacije: ozračevanje / Steriliseringsmetod: stråling / Sterilizasyon yöntemi: irradyasyon / Метод стерилизації: опроміненням / 灭菌方法: 辐射
	Biological Risks / Биологични рискове / Biologická rizika / Biologisk fare / Biogefährdung / Βιολογικοί κίνδυνοι / Riesgos biológicos / Bioloogilised riskid / Risques biologiques / Biološki rizik / Biológiallag veszélyes / Rischio biologico / Биологический тауекелдер / 생물학적 위험 / Biologinis pavojus / Biologiskie risici / Biologisk risiko / Biologisk risiko / Zagrożenia biologiczne / Perigo biológico / Riscuri biologice / Биологическая опасность / Biologické riziko / Biološki rizici / Biologisk risk / Biyolojik Riskler / Біологічна небезпека / 生物学风险
	Caution, consult accompanying documents / Внимание, направете справка в придружаващите документи / Pozor! Prostudujte si přiloženou dokumentaci! / Forsigtig, se ledsagende dokumenter / Achtung, Begleitdokumente beachten / Προσοχή, συμβουλευτείτε τα συνοδευτικά έγγραφα / Precaución, consultar la documentación adjunta / Ettevaatus! Lugeka kaasnevat dokumentatsiooni / Attention, consulter les documents joints / Upozorenje, koristi prateću dokumentaciju / Figyelem! Olvassa el a mellékelt tájékoztatót / Attenzione: consultare la documentazione allegata / Абайлаңыз, тиісті құжаттармен танысыңыз / 주의, 동봉된 설명서 참조 / Dămesio, ziți-rekite priedadamat dokumentus / Piesardzība, skatīt pavaddokumentus / Voorzichtig, raadpleeg bijgevoegde documenten / Forsiktig, se vedlagt dokumentasjon / Należy zapoznać się z dołączonymi dokumentami / Cuidado, consulte a documentação fornecida / Atenție, consultați documentele însoțitoare / Внимание: см. прилагаемую документацию / Výstraha, pozri sprievodné dokumenty / Pažnja! Pogledajte priložena dokumenta / Obs! Se medföljande dokumentation / Dikkat, birlikte verilen belgelere başvurun / Увага: див. супутню документацію / 小心, 请参阅附带文档。
	Upper limit of temperature / Горен лимит на температурата / Horní hranice teploty / Øvre temperaturgrænse / Temperaturobergrenze / Ανώτερο όριο θερμοκρασίας / Limite superior de temperatura / Ulemine temperatuuripiiri / Limite supérieure de température / Gornja dozvoljena temperatura / Felső hőmérsékleti határ / Limite superiore di temperatura / Температураның руқсат етілген жоғарғы шегі / 상한 온도 / Aukščiausia laikymo temperatūra / Augšējā temperatūras robeža / Hoogste temperatuurilimiet / Øvre temperaturgrense / Górná granica temperatury / Limite máximo de temperatura / Limită maximă de temperatură / Верхний предел температуры / Horná hranica teploty / Gornja granica temperature / Øvre temperaturgräns / Sicaklık üst sınırı / Максимальная температура / 温度上限
	Keep dry / Пазете сухо / Skladujte v suchém prostředí / Orbevares tørt / Trocklagern / Φυλάξτε το στεγνό / Maintenir seco / Hoida kuivas / Conserver au sec / Držati na suhom / Száraz helyen tartandó / Tenere all'asciutto / Құрғақ күйінде ұста / 건조 상태 유지 / Laikykite sausu / Uzglabāt sausu / Droog houden / Holds tørt / Przechowywać w stanie suchym / Manter seco / A se feri de umezeală / Не допускать попадания влаги / Uchovávajte v suchu / Držite na suvom mestu / Förvaras torrt / Kuru bir şekilde muhafaza edin / Берегти від вологи / 请保持干燥
	Collection time / Време на събиране / Čas odběru / Opsamlingstidspunkt / Entnahmeuhrzeit / Ώρα συλλογής / Hora de recogida / Kogumisaeg / Heure de prélèvement / Sati prikupljanja / Mintavétel időpontja / Ora di raccolta / Жинау уақыты / 수집 시간 / Paėmimo laikas / Savākšanas laiks / Verzameltijd / Tid prøvetaking / Godzina pobrania / Hora de colecta / Ora colectării / Време сбора / Doba odboru / Vreme prikupljanja / Uppsamlingstid / Toplama zamanı / Час забору / 采集时间
	Peel / Обенете / Otevíte zde / Åbn / Abziehen / Αποκολλήστε / Desprender / Koorida / Décoller / Otvoriti skini / Húzza le / Staccare / Ψτιγή қабатын алып таста / 벗기다 / Plęścić / Atīmēt / Schillen / Trek av / Oderwać / Destacar / Se dezlipște / Отклеить / Odrhните / Oljūstī / Dra isār / Ayırma / Відклеїти / 撕下
	Perforation / Перфорация / Perforace / Perforering / Διείσδυση / Perforación / Perforatsioon / Perforacija / Perforálás / Perforazione / Tecik tescy / 찢힘선 / Perforacija / Perforăcija / Perforatie / Perforacja / Perforação / Perforare / Перфорация / Perforácia / Perforasyon / Перфорация / 穿孔
	Do not use if package damaged / Не използвайте, ако опаковката е повредена / Nepoužívejte, je-li obal poškozený / Må ikke anvendes hvis emballagen er beskadiget / Inhal beschädigter Packungnicht verwenden / Μη χρησιμοποιείτε εάν η συσκευασία έχει υποστεί ζημιό. / No usar si el paquete está dañado / Mitte kasutada, kui pakend on kahjustatud / Ne pas l'utiliser si l'emballage est endommagé / Ne koristiti ako je oštećeno pakiranje / Ne használja, ha a csomagolás sérült / Non usare se la confezione è danneggiata / Егер пакет бұзылған болса, пайдаланба / 패키지가 손상된 경우 사용 금지 / Jei pakuotė pažeista, nenaudoti / Nelietot, ja iepakojums bojāts / Niet gebruiken indien de verpakking beschadigd is / Må ikke brukes hvis pakke er skadet / Nie używać, jeśli opakowanie jest uszkodzone / Não usar se a embalagem estiver danificada / A nu se folosi dacă pachetul este deteriorat / Не использовать при повреждении упаковки / Neporūžijajte, ak je obal poškodený / Ne koristite ako je pakovanje oštećeno / Använd ej om förpackningen är skadad / Ambalaj hasar görmüşse kullanmayın / Не використовувати за пошкодженої упаковки / 如果包装破损, 请勿使用
	Keep away from heat / Пазете от топлина / Nevstavujte přilísnému teplu / Må ikke udsættes for varme / Vor Wärme schützen / Κρατήστε το μακριά από τη θερμότητα / Mantener alejado de fuentes de calor / Hoida eemal valgusest / Protéger de la chaleur / Držati dalje od svjetla / Fény nem érheti / Tenere al riparo dalla luce / Қаpaңыланған жерде ұста / Ытөл пөкеаы аам / Laikyti atokiau nuo šilumos šaltinių / Sargāt no karstuma / Beschermen tegen warmte / Må ikke utsettes for varme / Przechowywać z dala od źródeł ciepła / Manter ao abrigo do calor / A se feri de căldură / Не нагревать / Uchovávajte mimo zdroja tepla / Držite dalje od toplote / Får ej utsättas för värme / Isidan uzak tutun / Берегти від дії тепла / 请远离热源
	Cut / Срежете / Odstřihněte / Klip / Schneiden / Κόψτε / Cortar / Lõigata / Découper / Rezi / Vágja ki / Tagliare / Keciřia / 잘라내기 / Kirpti / Nogriet / Knippen / Kutt / Odciać / Cortar / Decupați / Отрезать / Odstřihněte / Iseći / Klípp / Kesme / Pozpizati / 剪下
	Collection date / Дата на събиране / Datum odběru / Opsamlingsdato / Entnahmedatum / Ημερομηνία συλλογής / Fecha de recogida / Kogumiskuupäev / Date de prélèvement / Dani prikupljanja / Mintavétel dátuma / Data di raccolta / Жинаған тізбекүні / 수집 날짜 / Paėmimo data / Savākšanas datums / Verzameldatum / Dato prøvetaking / Data pobrania / Data de colecta / Ora colectării / Време сбора / Doba odboru / Datum prikupljanja / Uppsamlingsdatum / Toplama tarihi / Дата забору / 采集日期
	µL/test / µL/тест / µL/Test / µL/έξταση / µL/prueba / µL/teszt / µL/테스트 / мкл/тест / µL/tyrimas / µL/pārbaude / µL/teste / мкл/анализ / µL/检测
	Keep away from light / Пазете от светлина / Nevstavujte světlu / Må ikke udsættes for lys / Vor Licht schützen / Κρατήστε το μακριά από το φως / Mantener alejado de fuentes de luz / Hoida eemal valgusest / Conserver à l'abri de la lumière / Držati dalje od svjetla / Fény nem érheti / Tenere al riparo dalla luce / Қаpaңыланған жерде ұста / Ытөл пөкеаы аам / Laikyti atokiau nuo šilumos šaltinių / Sargāt no gaismas / Niet blootstellen aan zonlicht / Må ikke utsettes for lys / Przechowywać z dala od źródeł światła / Manter ao abrigo da luz / Ferij de lumină / Хранить в темноте / Uchovávajte mimo dosahu svetla / Držite dalje od svetlosti / Får ej utsättas för ljus / Işıktan uzak tutun / Берегти від дії світла / 请远离光线
	Hydrogen gas generated / Образуван е водород газ / Možnost úniku plyného vodíku / Frembringer hydrogengas / Wasserstoffgas erzeugt / Δημιουργία αερίου υδρογόνου / Producción de gas de hidrógeno / Vesinikugaasi tekitatud / Produit de l'hydrogène gazeux / Sadrži hidrogen vodik / Hidrogeen gázt fejleszt / Produzione di gas idrogeno / Газтөктөс сүлгөтөс пайда болды / 수소 가스 생성됨 / Išskiria vandenilio dujas / Rodas vandeninis / Waterstofgas gegenereerd / Hydrogengass generert / Powoduje powstawanie wodoru / Produção de gás de hidrogénio / Generare gaz de hidrogen / Выделение водорода / Vyrobené použitím vodíka / Oslobada se vodonik / Genererad vätgas / Açığa çıkan hidrojen gazı / Реакция з виділенням водню / 会产生氢气
	Patient ID number / ИД номер на пациента / ID pacienta / Patientens ID-nummer / Patienten-ID / Αριθμός αναγνώρισης ασθενούς / Número de ID del paciente / Patsiendi ID / No d'identification du patient / Identifikációs broj pacijenta / Beteg azonosító száma / Numero ID paziente / Пациенттің идентификациялық нөмірі / 환자 ID 번호 / Paciento identifikavimo numeris / Pacienta ID numurs / Identificatienummer van de patiënt / Patientsent ID-nummer / Nummer ID pacienta / Número da ID do doente / Numár ID pacient / Identifikacionnyj nomer pacijenta / Identifikačné číslo pacienta / ID broj pacijenta / Patientnummer / Hasta kimlik numarası / Идентификатор пациента / 患者标识号



Fragile, Handle with Care / Чупливо, Работете с необходимото внимание. / Křehké. Při manipulaci postupujte opatrně. / Forsigtig, kan gå i stykker. / Zerbrechlich, vorsichtig handhaben. / Εύθραστο. Χειριζτείτε το με προσοχή. / Frágil. Manipular con cuidado. / Őrn, kásitsege ettevaatlikult. / Fragile. Manipuler avec précaution. / Lomijivo, rukujte pažljivo. / Törékeny! Óvatosan kezelendő. / Fragile, maneggiare con cura. / Сынгыш, абайлап пайдаланыңыз. / 조심 깨지기 쉬운 처리 / Trapu, elkités atsargiai. / Trausls; rīkoties uzmanīgi / Breekbaar, voorzichtig behandelen. / Ømtålig, håndter forsigtig. / Krucha zawartość, przenosić ostrożnie. / Frágil, Manuseie com Cuidado. / Frágil, manipulați cu atenție. / Хрупкое! Обращаться с осторожностью. / Křehké, vyžaduje sa opatrná manipulácia. / Lomijivo - rukujte pažljivo. / Bräckligt. Hantera försiktigt. / Kolay Kırılır, Dikkatli Taşıyın. / Тендітна, звертатися з обережністю / 易碎, 小心轻放

**R<sub>x</sub> Only**

This only applies to US: "Caution: Federal Law restricts this device to sale by or on the order of a licensed practitioner." / S'applique uniquement aux États-Unis: "Caution: Federal Law restricts this device to sale by or on the order of a licensed practitioner." / Vale solo per gli Stati Uniti: "Caution: Federal Law restricts this device to sale by or on the order of a licensed practitioner." / Gilt nur für die USA: "Caution: Federal Law restricts this device to sale by or on the order of a licensed practitioner." / Sólo se aplica a los EE.UU.: "Caution: Federal Law restricts this device to sale by or on the order of a licensed practitioner."

 [bd.com/e-labeling](https://bd.com/e-labeling)



Technical Information: In the United States contact BD Technical Service and Support at 1.800.638.8663 or [bd.com](https://bd.com).



Becton, Dickinson and Company  
7 Loveton Circle  
Sparks, Maryland 21152 USA

Made in Canada.

BD, the BD Logo, ExK, and MAX are trademarks of Becton, Dickinson and Company or its affiliates. All other trademarks are the property of their respective owners. © 2020 BD. All rights reserved.



# Preparation of External Positive and Negative Controls for BD SARS-CoV-2 Reagents for BD MAX™ System

## Intended Use

The BD SARS-CoV-2 Reagents for BD MAX™ System is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in nasopharyngeal, nasal, mid-turbinate, and oropharyngeal swab specimens, nasopharyngeal wash/aspirate or nasal aspirates obtained from individuals suspected of COVID-19 by their healthcare provider. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform moderate or high complexity tests.<sup>1</sup>

Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in upper respiratory samples during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. Positive results should be treated as presumptive and should be tested with a different authorized or cleared molecular test. The agent detected may not be the definite cause of disease. Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities.<sup>1</sup>

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.<sup>1</sup>

The BD SARS-CoV-2 Reagents for BD MAX System is intended for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR, *in vitro* diagnostic procedures, and use of the BD MAX System. The BD SARS-CoV-2 Reagents for BD MAX™ System is only for use under the Food and Drug Administration's Emergency Use Authorization.<sup>1</sup>

## Purpose

According to the "Guidance for COVID-19 Testing for CAP-Accredited Laboratories" by the College of American Pathologists, clinical laboratories using EUA assays for COVID-19 testing must perform quality control each of day of patient testing.<sup>2</sup> External positive and negative controls are samples that act as surrogates for clinical specimens. They are processed like a clinical specimen to monitor the ongoing performance of the entire analytic process in every assay run.

The purpose of this document is to provide clinical laboratories with suggested procedures for preparing External Positive Controls (EPC) and External Negative Controls (ENC) for the BD SARS-CoV-2 Reagents on the BD MAX System using commercially prepared controls and materials.

**Table 1. Commercially Prepared Controls for SARS-CoV-2**

Manufacturer	SARS-CoV-2 Control	Other Control
BioGX SARS-CoV-2 & RNase P Synthetic Single- Stranded RNA Control Templates <sup>3</sup>	SARS-CoV-2 Nucleocapsid Phosphoprotein gene N1 SARS-CoV-2 Nucleocapsid Phosphoprotein gene N2	RNase P
Microbiologics® Helix Elite™ Synthetic RNA Standard <sup>4</sup>	1044 nucleotide segment of SARS-CoV-2 N (nucleocapsid) gene (N1, N2 and N3)	Negative Cellularity Control
Integrated DNA Technologies Positive Control Plasmids <sup>5,6</sup>	Complete 2019-nCoV Nucleocapsid gene (N1, N2 and N3)	Portion of the RPP30 single copy gene found in humans

Each suggested procedure for preparing an EPC or ENC has been verified by BD. However, the choice of EPC and ENC for the BD SARS-CoV-2 Reagents for BD MAX System is ultimately the decision of the laboratory, in accordance with applicable local, state, and/or federal regulations, accreditation requirements and the laboratory's standard Quality Control (QC) procedures.

### A) BioGX SARS-CoV-2 Nucleocapsid N1 and N2 genes and RNase P

The BioGX SARS-CoV-2 & RNase P Synthetic Single- Stranded RNA Control Templates kit contains lyophilized control template beads for the SARS-CoV-2 Nucleocapsid Phosphoprotein gene (N1), SARS-CoV-2 Nucleocapsid Phosphoprotein gene (N2), and RNase P.<sup>3</sup> The beads are formulated with quantified RNA (single stranded RNA) at  $1 \times 10^5$  copies per tube in a lyophilized bead format. Each product package contains 1 pouch of 24 tubes with each tube containing 1 lyophilized control template bead.<sup>3</sup> The BioGX SARS-CoV-2 & RNase P Synthetic Single- Stranded RNA Control Templates should be stored at 2-8°C.<sup>3</sup>

**Table 2. Materials Needed for the BioGX External Positive Controls**

Material	Part #
BioGX SARS-CoV-2 & RNase P Synthetic Single- Stranded RNA Control Templates	BD # 444214
BD MAX ExK TNA-3 Sample Buffer Tubes	BD # 442827 or 445003-01
Nuclease-free water*	Invitrogen # 4387936**

\*Alternate diluents e.g., Universal Transport Media (UTM) may be used for preparation of the Sample Buffer Tube if validated by the laboratory

\*\*or Equivalent

### Preparation of External Positive Controls (EPC) and External Negative Controls (ENC) from BioGX Control Beads

1. To prepare the SARS-CoV-2 N1 and N2 EPC, pipet 650 µL of nuclease-free water into a BD MAX ExK TNA-3 Sample Buffer Tube (SBT).
2. Rehydrate the BioGX SARS-CoV-2 N1 and N2 positive control beads individually with 100 µL of nuclease-free water.
3. Pipette the entire volume of the rehydrated N1 and N2 positive controls into the **same** SBT. Close the SBT with a blue septum cap and vortex or mix by inversion 5 times. Label the SBT as the SARS-CoV-2 N1/N2 EPC.
4. To prepare the RNase P positive control bead, repeat steps 1-3 above with a **new** BD MAX ExK TNA-3 SBT and the BioGX RNase P positive control beads. The rehydrated RNase P positive control bead

is added to the separate SBT.

5. Close the SBT with a blue septum cap and vortex or mix by inversion 5 times. Label the tube as the RNase P ENC.
6. Proceed with testing the prepared SARS-CoV-2 N1/N2 EPC SBT and the RNase P ENC SBT with the BD SARS-CoV-2 Reagents for BD MAX System according to instructions in the Package Insert.<sup>1</sup>

## Expected Results

Laboratories should refer to the BD SARS-CoV-2 Reagents for BD MAX System Package Insert for full interpretation of external control test results.<sup>1</sup> The expected results are below.

**Table 3. Expected results for the SARS-CoV-2 N1/N2 and RNase P External Controls**

External Positive Control	N1	N2	RNase P	COV-2	Result Interpretation
SARS CoV-2 N1/N2 EPC	Pos	Pos	N/A	Pos	Positive
RNase P ENC	Neg	Neg	Pos	Neg	Positive

*The SARS CoV-2 N1/N2 EPC and RNase P ENC should yield the expected positive results.*

## B) Microbiologics SARS-CoV-2 Synthetic RNA (N gene targets) and Negative Cellularity Control (RNaseP target)

The Microbiologics® Helix Elite™ SARS-CoV-2 synthetic RNA standard is a 1044-nucleotide portion of the SARS-CoV-2 N (nucleocapsid) gene containing the three markers N1, N2 and N3. Each kit includes 1 vial of dried synthetic RNA, 1 vial of molecular standard water, and a certificate of analysis.<sup>4</sup> The Helix Elite™ SARS-CoV-2 synthetic RNA standard should be stored at 2-25°C according to the manufacturer's instructions.<sup>4</sup> The Microbiologics® Helix Elite™ Negative Cellularity Control is specifically designed, full process controls containing A549 lung epithelial cells. Each kit contains 5 lyophilized pellets, packaged in individual vials<sup>5</sup>. The Negative Cellularity control serves as an RNaseP external negative control (ENC).

**Table 4. Materials Needed for the Microbiologics External Positive Control**

Material	Part #
Microbiologics® Helix Elite™ Synthetic Standard SARS-CoV-2 Synthetic RNA (N gene Targets)	Microbiologics # HE0060S
Microbiologics® Helix Elite™ Negative Cellularity Control (RNase P target)	Microbiologics #HE0058N
BD MAX ExK TNA-3 Sample Buffer Tubes	BD # 442827 or 445003-01
Molecular standard or Nuclease-free water*	Invitrogen # 4387936**
1X TE buffer, pH 8.0	Thermo Fisher Scientific # AM9849**
2 mL Tubes	VWR # 10025-756**

\*Alternate diluents e.g., Universal Transport Media (UTM) may be used for preparation of the Sample Buffer Tube if validated by the laboratory

\*\*or Equivalent

## Preparation of SARS-CoV-2 Synthetic RNA External Positive Control from Microbiologics Standard

1. To prepare the SARS-CoV-2 Synthetic RNA EPC, add 750 µL of nuclease-free water into a BD MAX ExK TNA-3 Sample Buffer Tube (SBT).
2. Rehydrate the lyophilized powder of the Helix Elite™ SARS-CoV-2 Synthetic RNA standard and dilute per the manufactures instructions<sup>4</sup>.
  - a. Add 55 µL of nuclease-free water for a concentration stock.



- b. Dilute the rehydrated SARS-CoV-2 Synthetic RNA by transferring the 90 µL of nuclease-free water to 10 µL of the concentrated stock.
3. Prepare the spiking dilution by adding 94.5 µL of nuclease-free water to 5.5 µL of the diluted stock.
4. Pipette 50 µL of the diluted stock into the SBT.
5. Close the SBT with a blue septum cap and vortex or mix by inversion 5 times. Label the tube as the SARS-CoV-2 Synthetic RNA EPC.
6. Proceed with testing the prepared SARS-CoV-2 Synthetic RNA EPC with the BD SARS-CoV-2 Reagents for BD MAX System according to instructions in the Package Insert.<sup>1</sup>

### Preparation of Negative Cellularity Control (RNaseP ENC) from Microbiologics

1. To prepare the Negative Cellularity Control, add 750 µL of nuclease-free water into a BD MAX ExK TNA-3 Sample Buffer Tube (SBT).
2. Rehydrate the lyophilized powder of the Helix Elite™ Negative Cellularity Control and dilute per the manufactures instructions<sup>5</sup>.
3. Add the rehydrated control to the sample buffer tube prepared in the step above.
4. Close the SBT with a blue septum cap and vortex or mix by inversion 5 times. Label the tube as the RNaseP EPC.
5. Proceed with testing the prepared RNaseP ENC with the BD SARS-CoV-2 Reagents for BD MAX System according to instructions in the Package Insert.<sup>1</sup>

### Expected Results

Laboratories should refer to the BD SARS-CoV-2 Reagents for BD MAX System Package Insert for full interpretation of external control test results.<sup>1</sup> The expected results are below.

**Table 5. Expected results for the SARS-CoV-2 Synthetic RNA External Positive and Negative Controls**

External Positive Control	N1	N2	RNase P	COV-2	Result Interpretation
SARS-CoV-2 Synthetic RNA EPC	Pos	Pos	N/A	Pos	Positive
Negative Cellularity Control (RNaseP ENC)	Neg	Neg	Pos	Neg	Positive

*The SARS-CoV-2 Synthetic RNA EPC and Negative Cellularity Control (RNaseP ENC) should yield the expected positive results.*

### C) IDT 2019-nCoV\_N and Hs\_RPP30 Positive Control Plasmids

The Integrated DNA Technologies (IDT) 2019-nCoV\_N Positive Control plasmid contains the complete nucleocapsid gene from 2019-nCoV (SARS-CoV-2). The Hs\_RPP30 Positive Control plasmid contains a portion of the RPP30 gene, a single copy gene present in the human genome.<sup>6,7</sup> The IDT control plasmids are derived from the CDC nCoV EUA kit. Control Plasmids are delivered at 250 µL (200,000 copies/µL) in IDTE, pH 8.0. Store at -20°C or colder.

**Table 6. Materials Needed for the IDT External Controls**

Material	Part #
IDT 2019-nCoV_N_Positive Control Plasmid	IDT # 10006625
IDT Hs_RPP30 Positive Control Plasmid	IDT # 10006626
ExK TNA-3 Sample Buffer Tubes	BD # 442827 or 445003-01
Nuclease-free water*	Invitrogen # 4387936**
1X TE, buffer pH 8.0	Thermo Fisher Scientific # AM9849**
2 mL Tubes	VWR # 10025-756**

\*Alternate diluents e.g., Universal Transport Media (UTM) may be used for preparation of the Sample Buffer Tube if validated by the laboratory

\*\*or Equivalent

## Preparation of External Positive Controls (EPC) and External Negative Controls (ENC) from IDT Control Plasmids

1. To prepare the 2019-nCoV\_N EPC add 750 µL of nuclease-free water into a BD MAX ExK TNA-3 Sample Buffer Tube (SBT).
2. Prepare a dilution of the stock IDT 2019-nCoV\_N Positive Control plasmid (200,000 copies/µL) in TE buffer (See Table 7 for dilution scheme).
3. Pipette 50 µL of the 200 copies/µL diluted stock into the SBT.
4. Close the SBT with a blue septum cap and vortex or mix by inversion 5 times. Label the SBT as the 2019-nCoV\_N EPC.
5. To prepare the Hs\_RPP30 EPC, repeat steps 1-3 above with a **new** BD MAX ExK TNA-3 SBT and the IDT Hs\_RPP30 Positive Control Plasmid.
6. Close the SBT with a blue septum cap and vortex or mix by inversion 5 times. Label the SBT as the Hs\_RPP30 ENC.
7. Proceed with testing the 2019-nCoV\_N EPC SBT and the Hs\_RPP30 ENC SBT with the BD SARS-CoV-2 Reagents for BD MAX System according to instructions in the Package Insert.<sup>1</sup>

**Table 7. IDT 2019-nCoV\_N and Hs\_RPP30 Plasmid Dilution Scheme**

Stock (cps/µL)	Dilution Factor	Total Volume of Buffer (µL)	Volume of Stock to Spike (µL)	Volume of TE buffer (µL)	Dilution Conc (cps/µL)
200,000	10	50	5	45	20,000
20,000	10	100	10	90	2,000
2,000	10	500	50	450	200

## Expected Results

Laboratories should refer to the BD SARS-CoV-2 Reagents for BD MAX System Package Insert for full interpretation of external control test results.<sup>1</sup> The expected results are below.

**Table 8. Expected results for the 2019-nCoV\_N and Hs\_RPP30 External Controls**

External Positive Control	N1	N2	RNase P	COV-2	Result Interpretation
2019-nCoV_N EPC	Pos	Pos	N/A	Pos	Positive
Hs_RPP30 ENC	Neg	Neg	Pos	Neg	Positive

The 2019-nCoV\_N EPC and Hs\_RPP30 ENC should yield the expected positive results.



## Expanding the Protocols

The example protocols described above may be expanded at the laboratory's discretion by increasing the number of each EPC for each run of the BD SARS-CoV-2 Reagents for BD MAX System. Please follow the Storage and Stability instructions in the respective Package Inserts of all media and materials used.

**IMPORTANT NOTE:** Laboratories should follow Good Laboratory Practices and Universal Precautions at all times during preparation and use of external control materials. All materials should be disposed of properly as required by the institution.

## Technical Service and Support

BD is committed to providing our customers timely and accurate support. If there are any questions or concerns about this document or the contents, please contact BD Life Sciences – Integrated Diagnostic Solutions Technical Service and Support by dialing 1-800-638-8663 (U.S.).

### References

- (1) BD SARS-CoV-2 Reagents for BD MAX™ System Package Insert. Becton Dickinson and Company, Sparks, MD. (Latest version).
- (2) College of American Pathologists "Guidance for COVID-19 Testing for CAP-Accredited Laboratories"  
<https://www.cap.org/laboratory-improvement/news-and-updates/guidance-for-covid-19-testing-for-cap-accredited-laboratories>  
Accessed March 21, 2020.
- (3) BioGX SARS-CoV-2 & RNase P Synthetic Single- Stranded RNA Control Templates. Package Insert (Latest version)
- (4) Microbiologics® Helix Elite™ Synthetic Standard SARS-CoV-2 Synthetic RNA (N Gene Targets). Package Insert (Latest version)
- (5) Microbiologics® Helix Elite™ Negative Cellularity Control. Package Insert (Latest version)
- (6) Integrated DNA Technologies 2019-nCoV\_N\_Positive Control Plasmid. Product Description (Latest version)
- (7) Integrated DNA Technologies Hs\_RPP30 Positive Control Plasmid. Product Description (Latest version)

BD, Sparks, MD 21152-0999 USA  
Tel: 800.638.8663

**bd.com**

BD, the BD Logo, ExK and MAX are trademarks of Becton, Dickinson and Company or its affiliates. All other trademarks are the property of their respective owners. © 2020 BD. All rights reserved.